DMT210 is our topical gel formulation that is specifically designed as a structural mimic of the amino acid tail found at the C-terminus of G-proteins with the purpose to downregulate the inflammatory response through G-protein coupled receptor (GPCR) signaling. Due to the wide distribution of GPCRs in the skin we plan to develop it for the treatment of rosacea, atopic dermatitis and acne vulgaris.
Rosacea: In vitro, DMT210 has demonstrated downregulation of TLR2, lowering IL-8 production. In addition, DMT210 also exhibited a reduction in IL-6, which is a powerful inflammatory mediator. Thus, DMT210 has the potential to be the first topical treatment to reduce both the erythema and the inflammation (papules and pustules) of rosacea.
Atopic Dermatitis: Another potential dermal indication for DMT210 is atopic dermatitis. The in vitro results of downregulation of TLR2/TLR4 resulted in the reduced levels of IL-6 and IL-8, DMT210 also reduced IL-4s and IL-17s produced by Peripheral Blood Mononuclear Cells, which are elevated in atopic dermatitis. IL-4 and IL-17 specifically increase migration of mast cells and eosinophils leading to degranulation and histamine release. Targeting both TLR and Th1/Th2 cytokines, as well as downstream G-protein signaling, DMT210 provides a multi-targeted, new approach in the treatment of atopic dermatitis.
Acne Vulgaris: We also believe that DMT210, as a potent Isoprenylcysteine analog, can reduce dermal inflammation in patients with inflammatory acne vulgaris. In vitro data suggests that with the downregulation of TLR2, coupled with the downregulation of G-protein-coupled receptor (GPCR), leading to a reduction in IL-6, DMT210 can be a powerful inflammatory mediator. Moreover, in vitro DMT210 has been shown to inhibit a P. acnes induced IL-8 response, as well as marked decreases in edema, erythema, and MPO in a mouse model of P. acnes induced inflammation. The structural configuration of DMT210, being a disodium salt that is highly soluble, gives DMT210 surfactant properties which may be useful in decreasing interfacial tension between the drug and the sebum. This promotes mixing in the form of an emulsion, providing a more favorable environment for drug partitioning and absorption. All these product attributes lead us to hypothesize that DMT210 could be a unique topical treatment for inflammatory acne vulgaris.
DMT220 is our novel ophthalmic formulation which we plan to develop for the treatment of ocular rosacea which affects about 50% of patients suffering with rosacea. Since many patients have both type of rosacea, we believe this disease can be diagnosed and treated by dermatologists, thus optimizing the API’s potential.
Ocular Rosacea: The ocular surface is also populated with GPCRs, suggesting that a topical ophthalmic formulation could be effective at targeting similar pathways as in the skin. Therefore, since the same inflammatory processes that occur in dermal rosacea are also expressed in ocular rosacea, there is good scientific rationale to develop DMT220 for ocular rosacea.
DMT310 is a topical sponge product that Dermata plans to develop for moderate to severe acne vulgaris. It contains a rare variant of freshwater sponge that is harvested from a protected location, under strict environmental conditions, using a stringent processing protocol. Based on years of research completed by Dr. Maria Villani, who discovered this unique sponge, she has found that harvesting this sponge from a consistent location at a particular time of year based on the monitoring of certain environmental conditions, such as outside air temperature, water temperature, dew point, relative humidity, actual and forecasted precipitation, and wind speed and direction, results in this sponge variant having a uniform chemical profile from batch to batch and year to year. We believe the uniform chemical profile of this patent protected sponge will play an important role in successfully developing DMT310 as a prescription product for the treatment of patients with moderate to severe acne vulgaris.